Bullish
$CLVS News will be coming out by June. Expect the stock to go up in advance before the following events: ***The company is planning to file an Investigational New Drug application (IND) for FAP-2286 in the second half of 2020. ***Phase 1b/2 study of Lucitanib in combination with Rucaparib in advanced ovarian cancer is also enrolling as an arm of the SEASTAR study. Initial data are anticipated at medical meetings beginning in mid-2020.
  • 3
  • 3